CompanyOLMANasdaqSan Francisco, CA

Olema Pharmaceuticals, Inc.

Olema Oncology develops estrogen receptor antagonists and degraders for breast cancer.

SEC EDGAR ClinicalTrials.gov olema.com

8-KAug 13Latest SEC filing, period to Aug 13

Aug 13Latest story

August 2026

Olema Oncology names Jason O'Byrne as chief financial officer

Aug 13PeopleOlema Pharmaceuticals, Inc.

Olema completes OPERA-01 enrollment, pushes top-line data to Q1 2027

Aug 10Quarterly updateOlema Pharmaceuticals, Inc.